vs
Side-by-side financial comparison of CareTrust REIT, Inc. (CTRE) and Esperion Therapeutics, Inc. (ESPR). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $134.9M, roughly 1.2× CareTrust REIT, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 55.1%). Over the past eight quarters, CareTrust REIT, Inc.'s revenue compounded faster (46.2% CAGR vs 10.6%).
CareTrust REIT, Inc.CTREEarnings & Financial Report
Target Healthcare REIT is a British property investment company which invests in healthcare properties and holds a large portfolio of care homes. It is structured as a real estate investment trust (REIT) and is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
CTRE vs ESPR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $134.9M | $168.4M |
| Net Profit | $111.3M | — |
| Gross Margin | — | — |
| Operating Margin | — | 50.6% |
| Net Margin | 82.5% | — |
| Revenue YoY | 55.1% | 143.7% |
| Net Profit YoY | 113.5% | — |
| EPS (diluted) | $0.52 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $134.9M | $168.4M | ||
| Q3 25 | $132.4M | $87.3M | ||
| Q2 25 | $112.5M | $82.4M | ||
| Q1 25 | $96.6M | $65.0M | ||
| Q4 24 | $86.9M | $69.1M | ||
| Q3 24 | $77.4M | $51.6M | ||
| Q2 24 | $68.9M | $73.8M | ||
| Q1 24 | $63.1M | $137.7M |
| Q4 25 | $111.3M | — | ||
| Q3 25 | $74.9M | $-31.3M | ||
| Q2 25 | $68.5M | $-12.7M | ||
| Q1 25 | $65.8M | $-40.5M | ||
| Q4 24 | $52.1M | — | ||
| Q3 24 | $33.4M | $-29.5M | ||
| Q2 24 | $10.8M | $-61.9M | ||
| Q1 24 | $28.7M | $61.0M |
| Q4 25 | — | 50.6% | ||
| Q3 25 | 58.1% | -11.4% | ||
| Q2 25 | 61.3% | 8.6% | ||
| Q1 25 | — | -34.0% | ||
| Q4 24 | — | -6.4% | ||
| Q3 24 | 43.0% | -31.0% | ||
| Q2 24 | 15.1% | 3.5% | ||
| Q1 24 | — | 52.5% |
| Q4 25 | 82.5% | — | ||
| Q3 25 | 56.6% | -35.9% | ||
| Q2 25 | 60.9% | -15.4% | ||
| Q1 25 | 68.1% | -62.2% | ||
| Q4 24 | 60.0% | — | ||
| Q3 24 | 43.2% | -57.2% | ||
| Q2 24 | 15.6% | -83.9% | ||
| Q1 24 | 45.6% | 44.3% |
| Q4 25 | $0.52 | $0.32 | ||
| Q3 25 | $0.35 | $-0.16 | ||
| Q2 25 | $0.35 | $-0.06 | ||
| Q1 25 | $0.35 | $-0.21 | ||
| Q4 24 | $0.30 | $-0.14 | ||
| Q3 24 | $0.21 | $-0.15 | ||
| Q2 24 | $0.07 | $-0.33 | ||
| Q1 24 | $0.22 | $0.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $198.0M | $167.9M |
| Total DebtLower is stronger | $894.2M | — |
| Stockholders' EquityBook value | $4.0B | $-302.0M |
| Total Assets | $5.1B | $465.9M |
| Debt / EquityLower = less leverage | 0.22× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $198.0M | $167.9M | ||
| Q3 25 | $712.5M | $92.4M | ||
| Q2 25 | $306.1M | $86.1M | ||
| Q1 25 | $26.5M | $114.6M | ||
| Q4 24 | $213.8M | $144.8M | ||
| Q3 24 | $377.1M | $144.7M | ||
| Q2 24 | $495.1M | $189.3M | ||
| Q1 24 | $451.2M | $226.6M |
| Q4 25 | $894.2M | — | ||
| Q3 25 | $893.8M | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $822.1M | — | ||
| Q4 24 | $396.9M | — | ||
| Q3 24 | $396.7M | — | ||
| Q2 24 | $671.1M | — | ||
| Q1 24 | $595.9M | — |
| Q4 25 | $4.0B | $-302.0M | ||
| Q3 25 | $4.0B | $-451.4M | ||
| Q2 25 | $3.3B | $-433.5M | ||
| Q1 25 | $2.9B | $-426.2M | ||
| Q4 24 | $2.9B | $-388.7M | ||
| Q3 24 | $2.4B | $-370.2M | ||
| Q2 24 | $1.9B | $-344.2M | ||
| Q1 24 | $1.7B | $-294.3M |
| Q4 25 | $5.1B | $465.9M | ||
| Q3 25 | $5.1B | $364.0M | ||
| Q2 25 | $4.7B | $347.1M | ||
| Q1 25 | $3.9B | $324.0M | ||
| Q4 24 | $3.4B | $343.8M | ||
| Q3 24 | $2.9B | $314.1M | ||
| Q2 24 | $2.7B | $352.3M | ||
| Q1 24 | $2.3B | $373.1M |
| Q4 25 | 0.22× | — | ||
| Q3 25 | 0.22× | — | ||
| Q2 25 | 0.35× | — | ||
| Q1 25 | 0.28× | — | ||
| Q4 24 | 0.14× | — | ||
| Q3 24 | 0.16× | — | ||
| Q2 24 | 0.35× | — | ||
| Q1 24 | 0.36× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $394.0M | $45.2M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | 3.54× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $394.0M | $45.2M | ||
| Q3 25 | $100.9M | $-4.3M | ||
| Q2 25 | $100.8M | $-31.4M | ||
| Q1 25 | $71.4M | $-22.6M | ||
| Q4 24 | $244.3M | $-35.0M | ||
| Q3 24 | $67.2M | $-35.3M | ||
| Q2 24 | $53.0M | $-7.2M | ||
| Q1 24 | $48.8M | $53.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-35.5M | ||
| Q2 24 | — | $-7.3M | ||
| Q1 24 | — | $53.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -68.7% | ||
| Q2 24 | — | -9.9% | ||
| Q1 24 | — | 39.0% |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | 0.1% | ||
| Q1 24 | — | 0.1% |
| Q4 25 | 3.54× | — | ||
| Q3 25 | 1.35× | — | ||
| Q2 25 | 1.47× | — | ||
| Q1 25 | 1.08× | — | ||
| Q4 24 | 4.68× | — | ||
| Q3 24 | 2.01× | — | ||
| Q2 24 | 4.92× | — | ||
| Q1 24 | 1.70× | 0.88× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTRE
Segment breakdown not available.
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
